Viral tropism, fitness and pathogenicity of HIV-1 subtype C

Future Virology

Volumn 5, Issue 2, 2010, Pages 219-231

  Jakobsen, Martin R ^a,b   Ellett, Anne ^a   Churchill, Melissa J ^a,c   Gorry, Paul R ^a,c,d  

^a BURNET INSTITUTE   (Australia)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

CCR5; Envelope; HIV 1; Macrophage; Pathogenesis subtype C

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

AFRICA; CD4 LYMPHOCYTE COUNT; DISEASE COURSE; DRUG EFFICACY; ENVIRONMENTAL FACTOR; FITNESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MACROPHAGE; MIXED INFECTION; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRAIN DIFFERENCE; TARGET CELL; VIRAL TROPISM; VIRUS ENTRY; VIRUS PATHOGENESIS; VIRUS STRAIN; VIRUS TRANSMISSION; VIRUS VIRULENCE;

EID: 77649321746     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/fvl.09.77     Document Type: Review

References (170)

1. United Nations Joint Programme on HIV/AIDS (UNAIDS): 2008 Report on the Global AIDS Epidemic. UNAIDS, Geneva, Switzerland (2008).
2. Mathers CD, Loncar D: Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 3(11), e442 (2006).
3. Arien KK, Vanham G, Arts EJ: Is HIV-1 evolving to a less virulent form in humans? Nat. Rev. Microbiol. 5(2), 141-151 (2007).
4. Hemelaar J, Gouws E, Ghys PD, Osmanov S: Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 20(16), W13-W23 (2006).
5. Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, Detours V: Evolutionary and immunological implications of contemporary HIV-1 variation. Br. Med. Bull. 58, 19-42 (2001).
6. Gao F, Robertson DL, Carruthers CD et al.: A comprehensive panel of near-full-length clones and reference sequences for non-subtype B isolates of human immunodeficiency virus type 1. J. Virol. 72(7), 5680-5698 (1998).
7. Subbarao S, Schochetman G: Genetic variability of HIV-1. AIDS 10(Suppl. A), S13-S23 (1996).
8. Gnanakaran S, Lang D, Daniels M, Bhattacharya T, Derdeyn CA, Korber B: Clade-specific differences between human immunodeficiency virus type 1 clades B and C: diversity and correlations in C3-V4 regions of gp120. J. Virol. 81(9), 4886-4891 (2007).
9. Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S: Molecular architecture of native HIV-1 gp120 trimers. Nature 455(7209), 109-113 (2008).
10. Wyatt R, Kwong PD, Desjardins E et al.: The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393(6686), 705-711 (1998).
11. Chan DC, Fass D, Berger JM, Kim PS: Core structure of gp41 from the HIV envelope glycoprotein. Cell 89(2), 263-273 (1997).
12. Gorry PR, Sterjovski J, Churchill M et al.: The role of viral coreceptors and enhanced macrophage tropism in human immunodeficiency virus type 1 disease progression. Sex. Health 1(1), 23-34 (2004).
13. Alkhatib G, Combadiere C, Broder CC et al.: CC CKR5: a RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 28, 272(5270), 1955-1958 (1996).
14. Choe H, Farzan M, Sun Y et al.: The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85(7), 1135-1148 (1996).
15. Deng H, Liu R, Ellmeier W et al.: Identification of a major co-receptor for primary isolates of HIV-1. Nature 381(6584), 661-666 (1996).
16. Doranz BJ, Rucker J, Yi Y et al.: A dual-tropic primary HIV-1 isolate that uses fusin and the β-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85(7), 1149-1158 (1996).
17. + cells is mediated by the chemokine receptor CC-CKR-5. Nature 381(6584), 667-673 (1996).
18. Feng Y, Broder CC, Kennedy PE, Berger EA: HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272(5263), 872-877 (1996).
19. Collman RG: HIV-1 Env-chemokine receptor interactions in primary human macrophages: entry and beyond. Res. Initiat. Treat. Action 8(2), 6-9 (2003).
20. Choe H, Farzan M, Konkel M et al.: The orphan seven-transmembrane receptor apj supports the entry of primary T-cell line-tropic and dualtropic human immunodeficiency virus type 1. J. Virol. 72(7), 6113-6118 (1998).
21. Combadiere C, Salzwedel K, Smith ED, Tiffany HL, Berger EA, Murphy PM: Identification of CX3CR1. A chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor for HIV-1. J. Biol. Chem. 273(37), 23799-23804 (1998).
22. Edinger AL, Hoffman TL, Sharron M, Lee B, O'Dowd B, Doms RW: Use of GPR1, GPR15, and STRL33 as coreceptors by diverse human immunodeficiency virus type 1 and simian immunodeficiency virus envelope proteins. Virology 249(2), 367-378 (1998).
23. Edinger AL, Hoffman TL, Sharron M et al.: An orphan seven-transmembrane domain receptor expressed widely in the brain functions as a coreceptor for human immunodeficiency virus type 1 and simian immunodeficiency virus. J. Virol. 72(10), 7934-7940 (1998).
24. Farzan M, Choe H, Martin K et al.: Two orphan seven-transmembrane segment receptors which are expressed in CD4-positive cells support simian immunodeficiency virus infection. J. Exp. Med. 186(3), 405-411 (1997).
25. Horuk R, Hesselgesser J, Zhou Y et al.: The CC chemokine I-309 inhibits CCR8-dependent infection by diverse HIV-1 strains. J. Biol. Chem. 273(1), 386-391 (1998).
26. Jinno A, Shimizu N, Soda Y, Haraguchi Y, Kitamura T, Hoshino H: Identification of the chemokine receptor TER1/CCR8 expressed in brain-derived cells and T cells as a new coreceptor for HIV-1 infection. Biochem. Biophys. Res. Commun. 243(2), 497-502 (1998).
27. Rucker J, Edinger AL, Sharron M et al.: Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses. J. Virol. 71(12), 8999-9007 (1997).
28. Samson M, Edinger AL, Stordeur P et al.: ChemR23, a putative chemoattractant receptor, is expressed in monocyte-derived dendritic cells and macrophages and is a coreceptor for SIV and some primary HIV-1 strains. Eur. J. Immunol. 28(5), 1689-1700 (1998).
29. Nedellec R, Coetzer M, Shimizu N et al.: Virus entry via the alternative coreceptors CCR3 and FPRL1 differs by human immunodeficiency virus type 1 subtype. J. Virol. 83(17), 8353-8363 (2009).
30. Shimizu N, Tanaka A, Oue A et al.: Broad usage spectrum of G protein-coupled receptors as coreceptors by primary isolates of HIV. AIDS 27(7), 761-769 (2009).
31. Shimizu N, Tanaka A, Mori T et al.: A formylpeptide receptor, FPRL1, acts as an efficient coreceptor for primary isolates of human immunodeficiency virus. Retrovirology 5, 52 (2008).
32. Kanbe K, Shimizu N, Soda Y, Takagishi K, Hoshino H: A CXC chemokine receptor, CXCR5/BLR1, is a novel and specific coreceptor for human immunodeficiency virus type 2. Virology 265(2), 264-273 (1999).
33. Cheng-Mayer C, Liu R, Landau NR, Stamatatos L: Macrophage tropism of human immunodeficiency virus type 1 and utilization of the CC-CKR5 coreceptor. J. Virol. 71(2), 1657-1661 (1997).
34. Cunningham AL, Li S, Juarez J, Lynch G, Alali M, Naif H: The level of HIV infection of macrophages is determined by interaction of viral and host cell genotypes. J. Leukoc. Biol. 68(3), 311-317 (2000).
35. Dittmar MT, McKnight A, Simmons G, Clapham PR, Weiss RA, Simmonds P: HIV-1 tropism and co-receptor use. Nature 385(6616), 495-496 (1997).
36. Gorry PR, Bristol G, Zack JA et al.: Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity. J. Virol. 75(21), 10073-10089 (2001).
37. + T cell counts in subtype C human immunodeficiency virus type 1-infected individuals from southern Africa. AIDS Res. Hum. Retroviruses 21(4), 285-291 (2005).
38. Hung CS, Pontow S, Ratner L: Relationship between productive HIV-1 infection of macrophages and CCR5 utilization. Virology 264(2), 278-288 (1999).
39. Peters PJ, Sullivan WM, Duenas-Decamp MJ et al.: Non-macrophage-tropic human immunodeficiency virus type 1 R5 envelopes predominate in blood, lymph nodes, and semen: implications for transmission and pathogenesis. J. Virol. 80(13), 6324-6332 (2006).
40. Doms RW, Peiper SC: Unwelcomed guests with master keys: how HIV uses chemokine receptors for cellular entry. Virology 235(2), 179-190 (1997).
41. Schuitemaker H, Koot M, Kootstra NA et al.: Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J. Virol. 66(3), 1354-1360 (1992).
42. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR: Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J. Exp. Med. 185(4), 621-628 (1997).
43. Scarlatti G, Tresoldi E, Bjorndal A et al.: In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat. Med. 3(11), 1259-1265 (1997).
44. Kaleebu P, Nankya IL, Yirrell DL et al.: Relation between chemokine receptor use, disease stage, and HIV-1 subtypes A and D: results from a rural Ugandan cohort. J. Acquir. Immune Defic. Syndr. 45(1), 28-33 (2007).
45. Huang W, Eshleman SH, Toma J et al.: Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations. J. Virol. 81(15), 7885-7893 (2007).
46. Berger EA, Murphy PM, Farber JM: Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17, 657-700 (1999).
47. Tscherning C, Alaeus A, Fredriksson R et al.: Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. Virology 241(2), 181-188 (1998).
48. Abebe A, Demissie D, Goudsmit J et al.: HIV-1 subtype C syncytium- and nonsyncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. AIDS 13(11), 1305-1311 (1999).
49. Batra M, Tien PC, Shafer RW, Contag CH, Katzenstein DA: HIV type 1 envelope subtype C sequences from recent seroconverters in Zimbabwe. AIDS Res. Hum. Retroviruses 16(10), 973-979 (2000).
50. Bjorndal A, Sonnerborg A, Tscherning C, Albert J, Fenyo EM: Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients. AIDS Res. Hum. Retroviruses 15(7), 647-653 (1999).
51. Cecilia D, Kulkarni SS, Tripathy SP, Gangakhedkar RR, Paranjape RS, Gadkari DA: Absence of coreceptor switch with disease progression in human immunodeficiency virus infections in India. Virology 271(2), 253-258 (2000).
52. Cilliers T, Nhlapo J, Coetzer M et al.: The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C: J. Virol. 77(7), 4449-4456 (2003).
53. Johnston ER, Zijenah LS, Mutetwa S, Kantor R, Kittinunvorakoon C, Katzenstein DA: High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatment. J. Virol. 77(13), 7682-7688 (2003).
54. Ping LH, Nelson JA, Hoffman IF et al.: Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: underrepresentation of X4 variants. J. Virol. 73(8), 6271-6281 (1999).
55. Abraha A, Nankya IL, Gibson R et al.: CCR5- and CXCR4-tropic subtype C human immunodeficiency virus type 1 isolates have a lower level of pathogenic fitness than other dominant group M subtypes: implications for the epidemic. J. Virol. 83(11), 5592-5605 (2009).
56. Michler K, Connell BJ, Venter WD, Stevens WS, Capovilla A, Papathanasopoulos MA: Genotypic characterization and comparison of full-length envelope glycoproteins from South African HIV type 1 subtype C primary isolates that utilize CCR5 and/or CXCR4. AIDS Res. Hum. Retroviruses 24(5), 743-751 (2008).
57. Connell BJ, Michler K, Capovilla A, Venter WD, Stevens WS, Papathanasopoulos MA: Emergence of X4 usage among HIV-1 subtype C: evidence for an evolving epidemic in South Africa. AIDS 22(7), 896-899 (2008).
58. Kassaye S, Johnston E, McColgan B, Kantor R, Zijenah L, Katzenstein D: Envelope coreceptor tropism, drug resistance, and viral evolution among subtype C HIV-1-infected individuals receiving nonsuppressive antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 50(1), 9-18 (2009).
59. Derdeyn CA, Decker JM, Bibollet-Ruche F et al.: Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303(5666), 2019-2022 (2004).
60. Chohan B, Lang D, Sagar M et al.: Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J. Virol. 79(10), 6528-6531 (2005).
61. Isaacman-Beck J, Hermann EA, Yi Y et al.: Heterosexual transmission of human immunodeficiency virus type 1 subtype C: Macrophage tropism, alternative coreceptor use, and the molecular anatomy of CCR5 utilization. J. Virol. 83(16), 8208-8220 (2009).
62. Moore PL, Ranchobe N, Lambson BE et al.: Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog. 5(9), e1000598 (2009).
63. Frost SD, Wrin T, Smith DM et al.: Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc. Natl Acad. Sci. USA 102(51), 18514-18519 (2005).
64. Frost SD, Liu Y, Pond SL et al.: Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B. J. Virol. 79(10), 6523-6527 (2005).
65. Long EM, Martin HL Jr, Kreiss JK et al.: Gender differences in HIV-1 diversity at time of infection. Nat. Med. 6(1), 71-75 (2000).
66. Sagar M, Kirkegaard E, Lavreys L, Overbaugh J: Diversity in HIV-1 envelope V1-V3 sequences early in infection reflects sequence diversity throughout the HIV-1 genome but does not predict the extent of sequence diversity during chronic infection. AIDS Res. Hum. Retroviruses 22(5), 430-437 (2006).
67. Haaland RE, Hawkins PA, Salazar-Gonzalez J et al.: Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog. 5(1), e1000274 (2009).
68. Kearney M, Maldarelli F, Shao W et al.: Human immunodeficiency virus type 1 population genetics and adaptation in newly infected individuals. J. Virol. 83(6), 2715-2727 (2009).
69. Buchacz KA, Wilkinson DA, Krowka JF, Koup RA, Padian NS: Genetic and immunological host factors associated with susceptibility to HIV-1 infection. AIDS 12(Suppl A), S87-S94 (1998).
70. Fauci AS: Host factors and the pathogenesis of HIV-induced disease. Nature 384(6609), 529-534 (1996).
71. Fauci AS, Pantaleo G, Stanley S, Weissman D: Immunopathogenic mechanisms of HIV infection. Ann. Intern. Med. 124(7), 654-663 (1996).
72. Mikhail IS, DiClemente R, Person S et al.: Association of complementary and alternative medicines with HIV clinical disease among a cohort of women living with HIV/AIDS. J. Acquir. Immune Defic. Syndr. 37(3), 1415-1422 (2004).
73. Rowland-Jones S, Pinheiro S, Kaul R: New insights into host factors in HIV-1 pathogenesis. Cell 104(4), 473-476 (2001).
74. Tuttle DL, Anders CB, Aquino-De Jesus MJ et al.: Increased replication of non-syncytium-inducing HIV type 1 isolates in monocyte-derived macrophages is linked to advanced disease in infected children. AIDS Res. Hum. Retroviruses 18(5), 353-362 (2002).
75. Li S, Juarez J, Alali M et al.: Persistent CCR5 utilization and enhanced macrophage tropism by primary blood human immunodeficiency virus type 1 isolates from advanced stages of disease and comparison to tissue-derived isolates. J. Virol. 73(12), 9741-9755 (1999).
76. Lewin SR, Sonza S, Irving LB, McDonald CF, Mills J, Crowe SM: Surface CD4 is critical to in vitro HIV infection of human alveolar macrophages. AIDS Res. Hum. Retroviruses 12(10), 877-883 (1996).
77. Ometto L, Zanchetta M, Cabrelle A et al.: Restriction of HIV type 1 infection in macrophages heterozygous for a deletion in the CC-chemokine receptor 5 gene. AIDS Res. Hum. Retroviruses 15(16), 1441-1452 (1999).
78. Wang J, Crawford K, Yuan M, Wang H, Gorry PR, Gabuzda D: Regulation of CC chemokine receptor 5 and CD4 expression and human immunodeficiency virus type 1 replication in human macrophages and microglia by T helper type 2 cytokines. J. Infect. Dis. 185(7), 885-897 (2002).
79. Bannert N, Schenten D, Craig S, Sodroski J: The level of CD4 expression limits infection of primary rhesus monkey macrophages by a T-tropic simian immunodeficiency virus and macrophagetropic human immunodeficiency viruses. J. Virol. 74(23), 10984-10993 (2000).
80. Mori K, Yasutomi Y, Sawada S et al.: Suppression of acute viremia by short-term postexposure prophylaxis of simian/human immunodeficiency virus SHIV-RT-infected monkeys with a novel reverse transcriptase inhibitor (GW420867) allows for development of potent antiviral immune responses resulting in efficient containment of infection. J. Virol. 74(13), 5747-5753 (2000).
81. Fear WR, Kesson AM, Naif H, Lynch GW, Cunningham AL: Differential tropism and chemokine receptor expression of human immunodeficiency virus type 1 in neonatal monocytes, monocyte-derived macrophages, and placental macrophages. J. Virol. 72(2), 1334-1344 (1998).
82. Kuhmann SE, Platt EJ, Kozak SL, Kabat D: Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1. J. Virol. 74(15), 7005-7015 (2000).
83. Rana S, Besson G, Cook DG et al.: Role of CCR5 in infection of primary macrophages and lymphocytes by macrophage-tropic strains of human immunodeficiency virus: resistance to patient-derived and prototype isolates resulting from the δ ccr5 mutation. J. Virol. 71(4), 3219-3227 (1997).
84. Reynes J, Portales P, Segondy M et al.: CD4 T cell surface CCR5 density as a host factor in HIV-1 disease progression. AIDS 15(13), 1627-1634 (2001).
85. Tuttle DL, Harrison JK, Anders C, Sleasman JW, Goodenow MM: Expression of CCR5 increases during monocyte differentiation and directly mediates macrophage susceptibility to infection by human immunodeficiency virus type 1. J. Virol. 72(6), 4962-4969 (1998).
86. Peters PJ, Duenas-Decamp MJ, Sullivan WM et al.: Variation in HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block envelope: CD4 interactions but not with sensitivity to other entry inhibitors. Retrovirology 5, 5 (2008).
87. Rossi F, Querido B, Nimmagadda M, Cocklin S, Navas-Martin S, Martin-Garcia J: The V1-V3 region of a brain-derived HIV-1 envelope glycoprotein determines macrophage tropism, low CD4 dependence, increased fusogenicity and altered sensitivity to entry inhibitors. Retrovirology 5, 89 (2008).
88. Martin-Garcia J, Cao W, Varela-Rohena A, Plassmeyer ML, Gonzalez-Scarano F: HIV-1 tropism for the central nervous system: brain-derived envelope glycoproteins with lower CD4 dependence and reduced sensitivity to a fusion inhibitor. Virology 346(1), 169-179 (2006).
89. Thomas ER, Dunfee RL, Stanton J et al.: Macrophage entry mediated by HIV Envs from brain and lymphoid tissues is determined by the capacity to use low CD4 levels and overall efficiency of fusion. Virology 360(1), 105-119 (2007).
90. Peters PJ, Duenas-Decamp MJ, Sullivan WM, Clapham PR: Variation of macrophage tropism among HIV-1 R5 envelopes in brain and other tissues. J. Neuroimmune Pharmacol. 2(1), 32-41 (2007).
91. Martin J, LaBranche CC, Gonzalez-Scarano F: Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate. J. Virol. 75(8), 3568-3580 (2001).
92. Dunfee RL, Thomas ER, Wang J, Kunstman K, Wolinsky SM, Gabuzda D: Loss of the N-linked glycosylation site at position 386 in the HIV envelope V4 region enhances macrophage tropism and is associated with dementia. Virology 367(1), 222-234 (2007).
93. Dunfee RL, Thomas ER, Gabuzda D: Enhanced macrophage tropism of HIV in brain and lymphoid tissues is associated with sensitivity to the broadly neutralizing CD4 binding site antibody b12. Retrovirology 6, 69 (2009).
94. Duenas-Decamp MJ, Peters PJ, Burton D, Clapham PR: Determinants flanking the CD4 binding loop modulate macrophage tropism of human immunodeficiency virus type 1 R5 envelopes. J. Virol. 83(6), 2575-2583 (2009).
95. Dunfee RL, Thomas ER, Gorry PR et al.: The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia. Proc. Natl Acad. Sci. USA 103(41), 15160-15165 (2006).
96. Gorry PR, Taylor J, Holm GH et al.: Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. J. Virol. 76(12), 6277-6292 (2002).
97. Ball SC, Abraha A, Collins KR et al.: Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C. J. Virol. 77(2), 1021-1038 (2003).
98. Pollakis G, Abebe A, Kliphuis A et al.: Phenotypic and genotypic comparisons of CCR5- and CXCR4-tropic human immunodeficiency virus type 1 biological clones isolated from subtype C-infected individuals. J. Virol. 78(6), 2841-2852 (2004).
99. Etemad B, Fellows A, Kwambana B et al.: Human immunodeficiency virus type 1 V1-to-V5 envelope variants from the chronic phase of infection use CCR5 and fuse more efficiently than those from early after infection. J. Virol. 83(19), 9694-9708 (2009).
100. Clerici M, Butto S, Lukwiya M et al.: Immune activation in africa is environmentally-driven and is associated with upregulation of CCR5. Italian-Ugandan AIDS Project. AIDS 14(14), 2083-2092 (2000).
101. Kalinkovich A, Borkow G, Weisman Z, Tsimanis A, Stein M, Bentwich Z: Increased CCR5 and CXCR4 expression in Ethiopians living in Israel: environmental and constitutive factors. Clin. Immunol. 100(1), 107-117 (2001).
102. + CD4 T cells among south Indian adults probably associated with the low frequency of X4 phenotype of HIV-1 in India. Indian J. Med. Res. 116, 90-95 (2002).
103. Dubey S, Khalid M, Wesley C, Khan SA, Wanchu A, Jameel S: Downregulation of CCR5 on activated CD4 T cells in HIV-infected Indians. J. Clin. Virol. 43(1), 25-31 (2008).
104. Rodriguez MA, Ding M, Ratner D et al.: High replication fitness and transmission efficiency of HIV-1 subtype C from India: Implications for subtype C predominance. Virology 385(2), 416-424 (2009).
105. John-Stewart GC, Nduati RW, Rousseau CM et al.: Subtype C is associated with increased vaginal shedding of HIV-1. J. Infect. Dis. 192(3), 492-496 (2005).
106. Iversen AK, Learn GH, Skinhoj P, Mullins JI, McMichael AJ, Rambaut A: Preferential detection of HIV subtype Ć over subtype A in cervical cells from a dually infected woman. AIDS 19(9), 990-993 (2005).
107. Fontella R, Soares MA, Schrago CG: On the origin of HIV-1 subtype C in South America. AIDS 22(15), 2001-2011 (2008).
108. Rainwater S, DeVange S, Sagar M et al.: No evidence for rapid subtype C spread within an epidemic in which multiple subtypes and intersubtype recombinants circulate. AIDS Res. Hum. Retroviruses 21(12), 1060-1065 (2005).
109. Shankarappa R, Chatterjee R, Learn GH et al.: Human immunodeficiency virus type 1 env sequences from Calcutta in eastern India: identification of features that distinguish subtype C sequences in India from other subtype C sequences. J. Virol. 75(21), 10479-10487 (2001).
110. Soares EA, Santos RP, Pellegrini JA, Sprinz E, Tanuri A, Soares MA: Epidemiologic and molecular characterization of human immunodeficiency virus type 1 in southern Brazil. J. Acquir. Immune Defic. Syndr. 34(5), 520-526 (2003).
111. Fontella R, Soares MA, Schrago CG: The origin of South American HIV-1 subtype C: lack of evidence for a Mozambican ancestry. AIDS 23(14), 1926-1928 (2009).
112. de Macedo Brigido LF: On the origin of South America HIV-1 C epidemic. AIDS 23(4), 543-544 (2009).
113. Jones LR, Dilernia DA, Manrique JM, Moretti F, Salomon H, Gomez-Carrillo M: In-depth analysis of the origins of HIV type 1 subtype C in South America. AIDS Res. Hum. Retroviruses 25(10), 951-959 (2009).
114. Bentwich Z, Kalinkovich A, Weisman Z: Immune activation is a dominant factor in the pathogenesis of African AIDS. Immunol. Today 16(4), 187-191 (1995).
115. Rizzardini G, Piconi S, Ruzzante S et al.: Immunological activation markers in the serum of African and European HIV-seropositive and seronegative individuals. AIDS 10(13), 1535-1542 (1996).
116. Rizzardini G, Trabattoni D, Saresella M et al.: Immune activation in HIV-infected African individuals. Italian-Ugandan AIDS cooperation program. AIDS 12(18), 2387-2396 (1998).
117. Lukwiya M, Rizzardini G, Trabattoni D et al.: Evaluation of immune activation in HIV-infected and uninfected African individuals by single-cell analysis of cytokine production. J. Acquir. Immune Defic. Syndr. 28(5), 429-436 (2001).
118. Loetscher M, Gerber B, Loetscher P et al.: Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J. Exp. Med. 184(3), 963-969 (1996).
119. Loetscher P, Seitz M, Baggiolini M, Moser B: Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes. J. Exp. Med. 184(2), 569-577 (1996).
120. Sozzani S, Ghezzi S, Iannolo G et al.: Interleukin 10 increases CCR5 expression and HIV infection in human monocytes. J. Exp. Med. 187(3), 439-444 (1998).
121. Houle M, Thivierge M, Le Gouill C, Stankova J, Rola-Pleszczynski M: IL-10 up-regulates CCR5 gene expression in human monocytes. Inflammation 23(3), 241-251 (1999).
122. Kootstra NA, van 't Wout A, Huisman HG, Miedema F, Schuitemaker H: Interference of interleukin-10 with human immunodeficiency virus type 1 replication in primary monocyte-derived macrophages. J. Virol. 68(11), 6967-6975 (1994).
123. Chang J, Naif HM, Li S, Jozwiak R, Ho-Shon M, Cunningham AL: The inhibition of HIV replication in monocytes by interleukin 10 is linked to inhibition of cell differentiation. AIDS Res. Hum. Retroviruses 12(13), 1227-1235 (1996).
124. Hoshino Y, Tse DB, Rochford G et al.: Mycobacterium tuberculosis-induced CXCR4 and chemokine expression leads to preferential X4 HIV-1 replication in human macrophages. J. Immunol. 172(10), 6251-6258 (2004).
125. + T cells during human endotoxemia and after stimulation with (myco)bacterial antigens: the role of cytokines. Blood 96(8), 2649-2654 (2000).
126. Rosas-Taraco AG, Arce-Mendoza AY, Caballero-Olin G, Salinas-Carmona MC: Mycobacterium tuberculosis upregulates coreceptors CCR5 and CXCR4 while HIV modulates CD14 favoring concurrent infection. AIDS Res. Hum. Retroviruses 22(1), 45-51 (2006).
127. + T cells and plasma chemokine levels during treatment of active tuberculosis in HIV-1-coinfected patients. J. Acquir. Immune Defic. Syndr. 39(3), 265-271 (2005).
128. Morris L, Cilliers T, Bredell H, Phoswa M, Martin DJ: CCR5 is the major coreceptor used by HIV-1 subtype C isolates from patients with active tuberculosis. AIDS Res. Hum. Retroviruses 17(8), 697-701 (2001).
129. Lawn SD, Churchyard G: Epidemiology of HIV-associated tuberculosis. Curr. Opin. HIV AIDS 4(4), 325-333 (2009).
130. Gorry PR, Zhang C, Wu S et al.: Persistence of dual-tropic HIV-1 in an individual homozygous for the CCR5 d32 allele. Lancet 359(9320), 1832-1834 (2002).
131. + monocyte subset preferentially harbors HIV-1 and is expanded in pregnant Malawian women with Plasmodium falciparum malaria and HIV-1 infection. J. Infect. Dis. 196(1), 38-42 (2007).
132. Tkachuk AN, Moormann AM, Poore JA et al.: Malaria enhances expression of CC chemokine receptor 5 on placental macrophages. J. Infect. Dis. 183(6), 967-972 (2001).
133. Lawn SD, Karanja DM, Mwinzia P et al.: The effect of treatment of schistosomiasis on blood plasma HIV-1 RNA concentration in coinfected individuals. AIDS 14(16), 2437-2443 (2000).
134. Erikstrup C, Kallestrup P, Zinyama-Gutsire RB et al.: Schistosomiasis and infection with human immunodeficiency virus 1 in rural Zimbabwe: systemic inflammation during co-infection and after treatment for schistosomiasis. Am. J. Trop. Med. Hyg. 79(3), 331-337 (2008).
135. Kallestrup P, Zinyama R, Gomo E et al.: Schistosomiasis and HIV-1 infection in rural Zimbabwe: effect of treatment of schistosomiasis on CD4 cell count and plasma HIV-1 RNA load. J. Infect. Dis. 192(11), 1956-1961 (2005).
136. Leutscher PD, Pedersen M, Raharisolo C et al.: Increased prevalence of leukocytes and elevated cytokine levels in semen from Schistosoma haematobium-infected individuals. J. Infect. Dis. 191(10), 1639-1647 (2005).
137. Kallestrup P, Zinyama R, Gomo E et al.: Schistosomiasis and HIV-1 infection in rural Zimbabwe: implications of coinfection for excretion of eggs. J. Infect. Dis. 191(8), 1311-1320 (2005).
138. + T cells and monocytes of patients with Schistosoma mansoni infection. Infect. Immun. 71(11), 6668-6671 (2003).
139. Erikstrup C, Kallestrup P, Zinyama-Gutsire RB et al.: Reduced mortality and CD4 cell loss among carriers of the interleukin-10-1082G allele in a Zimbabwean cohort of HIV-1-infected adults. AIDS 21(17), 2283-2291 (2007).
140. Arien KK, Abraha A, Quinones-Mateu ME, Kestens L, Vanham G, Arts EJ: The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates. J. Virol. 79(14), 8979-8990 (2005).
141. Marozsan AJ, Moore DM, Lobritz MA et al.: Differences in the fitness of two diverse wild-type human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry. J. Virol. 79(11), 7121-7134 (2005).
142. Morgan D, Mahe C, Mayanja B, Okongo JM, Lubega R, Whitworth JA: HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries? AIDS 16(4), 597-603 (2002).
143. The CASCADE Collaboration: Survival after introduction of HAART in people with known duration of HIV-1 infection. Concerted Action on Sero Conversion to AIDS and Death in Europe. Lancet 355(9210), 1158-1159 (2000).
144. No authors listed: Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action on Sero Conversion to AIDS and Death in Europe. Lancet 355(9210), 1131-1137 (2000).
145. Lyles CM, Dorrucci M, Vlahov D et al.: Longitudinal human immunodeficiency virus type 1 load in the italian seroconversion study: correlates and temporal trends of virus load. J. Infect. Dis. 180(4), 1018-1024 (1999).
146. Del Amo J, Petruckevitch A, Phillips A et al.: Disease progression and survival in HIV-1-infected Africans in London. AIDS 12(10), 1203-1209 (1998).
147. + cell counts. J. Infect. Dis. 169(6), 1236-1243 (1994).
148. Lohse N, Hansen AB, Pedersen G et al.: Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann. Intern. Med. 146(2), 87-95 (2007).
149. Galai N, Kalinkovich A, Burstein R, Vlahov D, Bentwich Z: African HIV-1 subtype C and rate of progression among Ethiopian immigrants in Israel. Lancet 349(9046), 180-181 (1997).
150. Alaeus A, Lidman K, Bjorkman A, Giesecke J, Albert J: Similar rate of disease progression among individuals infected with HIV-1 genetic subtypes A-D. AIDS 13(8), 901-907 (1999).
151. Baeten JM, Chohan B, Lavreys L et al.: HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J. Infect. Dis. 195(8), 1177-1180 (2007).
152. Kiwanuka N, Laeyendecker O, Robb M et al.: Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J. Infect. Dis. 197(5), 707-713 (2008).
153. Daar ES, Kesler KL, Petropoulos CJ et al.: Baseline HIV type 1 coreceptor tropism predicts disease progression. Clin. Infect. Dis. 45(5), 643-649 (2007).
154. Goetz MB, Leduc R, Kostman JR et al.: Relationship between HIV coreceptor tropism and disease progression in persons with untreated chronic HIV infection. J. Acquir. Immune Defic. Syndr. 50(3), 259-266 (2009).
155. Frater AJ, Dunn DT, Beardall AJ et al.: Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy. AIDS 16(8), 1139-1146 (2002).
156. Pillay D, Walker AS, Gibb DM et al.: Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial. J. Infect. Dis. 186(5), 617-625 (2002).
157. Stringer JS, Zulu I, Levy J et al.: Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 296(7), 782-793 (2006).
158. Wester CW, Kim S, Bussmann H et al.: Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana. J. Acquir. Immune Defic. Syndr. 40(3), 336-343 (2005).
159. Weidle PJ, Malamba S, Mwebaze et al.: Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet 360(9326), 34-40 (2002).
160. Weidle PJ, Mastro TD, Grant AD, Nkengasong J, Macharia D: HIV/AIDS treatment and HIV vaccines for Africa. Lancet 359(9325), 2261-2267 (2002).
161. Ferradini L, Jeannin A, Pinoges L et al.: Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 367(9519), 1335-1342 (2006).
162. Hawkins C, Achenbach C, Fryda W, Ngare D, Murphy R: Antiretroviral durability and tolerability in HIV-infected adults living in urban Kenya. J. Acquir. Immune Defic. Syndr. 45(3), 304-310 (2007).
163. Etard JF, Ndiaye I, Thierry-Mieg M et al.: Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 20(8), 1181-1189 (2006).
164. Braitstein P, Brinkh of MW, Dabis F et al.: Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367(9513), 817-824 (2006).
165. Bussmann H, Wester CW, Ndwapi N et al.: Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program. AIDS 22(17), 2303-2311 (2008).
166. Geretti AM, Harrison L, Green H et al.: Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin. Infect. Dis. 48(9), 1296-1305 (2009).
167. Cassol E, Page T, Mosam A et al.: Therapeutic response of HIV-1 subtype C in African patients coinfected with either Mycobacterium tuberculosis or human herpesvirus-8. J. Infect. Dis. 191(3), 324-332 (2005).
168. Hoffmann CJ, Charalambous S, Sim J et al.: Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin. Infect. Dis. 49(12), 1928-1935 (2009).
169. Johannessen A, Naman E, Kivuyo SL et al.: Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania. BMC Infect. Dis. 9, 108 (2009).
170. van Oosterhout JJ, Brown L, Weigel R et al.: Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteria. Trop. Med. Int. Health 14(8), 856-861 (2009).